AAPG vs ZYBT
Ascentage Pharma Group International and Zhengye Biotechnology Holding Limited, side by side — 3 fiscal years reported in CNY, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | AAPG | ZYBT |
|---|---|---|
| Revenue | ¥980.6M | ¥116.4M |
| Net income | ¥-405.4M | ¥-69.8M |
| Gross margin | 97.0% | 20.5% |
| Net margin | −41.3% | −60.0% |
| Return on equity | −249.8% | −26.1% |
| Diluted EPS | −¥1.34 | ¥0.25 |
| Dividend / share | — | — |
| Payout ratio | — | 141.7% |
| Free cash flow | ¥-135.6M | ¥12.3M |
| Equity | ¥264.2M | ¥249.8M |
| Net debt / equity | 2.93× | −0.16× |
| Current ratio | 1.26× | 1.14× |
| Revenue CAGR 5y | — | — |
| Profit CAGR 5y | — | — |
AAPG bills 8.4× the revenue of ZYBT, and both closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
3 years side by side
| Fiscal year | AAPG | ZYBT |
|---|---|---|
| FY2024 | ¥980.6M | ¥186.4M |
| FY2023 | ¥222.0M | ¥211.7M |
| FY2022 | ¥209.7M | ¥260.3M |
Net income by year
Bottom line
| Fiscal year | AAPG | ZYBT |
|---|---|---|
| FY2024 | ¥-405.4M | ¥11.3M |
| FY2023 | ¥-925.6M | ¥31.5M |
| FY2022 | ¥-882.9M | ¥46.7M |
Advertisement
AdSense · Rectangle 336×280
The companies